Considering both the limitations of insulin usage and the advantages of weekly GLP-1 receptor analog administration with respect to the ease of injection and therapeutic targeting toward the intestine, brain, and pancreas (15), we hypothesized the applicability of switching to weekly GLP-1 receptor analogs from insulin in patients with T2D whose HbA1c levels were 7.6% or higher. Here, INS is linked to type 2 diabetes mellitus.